Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis

Cytochrome P450 is a family of enzymes that catalyze reactions involved in the metabolism of drugs and other xenobiotics. These enzymes are therefore important in pharmacologic and toxicologic studies, and information on their abundances is of value in the process of scaling in vitro data to in vivo metabolic parameters. A meta-analysis was applied to data on the abundance of human hepatic cytochrome P450 enzymes in Caucasian adult livers (50 studies). Despite variations in the methods used to measure the abundance of enzymes, agreement between the studies in 26 different laboratories was generally good. Nonetheless, some heterogeneity was detected (Higgins and Thompson heterogeneity test). More importantly, large interindividual variability was observed in the collated data. Positive correlations between the expression levels of some cytochrome P450 enzymes were found in the abundance data, including the following pairs: CYP3A4/CYP3A5*1/*3 (Rs = 0.70, P < 0.0001, n = 52), CYP3A4/CYP2C8 (Rs = 0.68, P < 0.0001, n = 134), CYP3A4/CYP2C9 (Rs = 0.55, P < 0.0001, n = 71), and CYP2C8/CYP2C9 (Rs = 0.55, P < 0.0001, n = 99). These correlations can be used to demonstrate common genetic transcriptional mechanisms.

[1]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[2]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[3]  O. Olesen,et al.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. , 2008, British journal of clinical pharmacology.

[4]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[5]  Julio Sánchez-Meca,et al.  Homogeneity tests in meta-analysis: a Monte Carlo comparison of statistical power and Type I error , 1997 .

[6]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[7]  D. Waxman,et al.  Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Amin Rostami-Hodjegan,et al.  Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  W. Griffiths,et al.  Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. , 2009, Journal of proteome research.

[10]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[11]  E. Kharasch,et al.  Role of CYP2B6 in Stereoselective Human Methadone Metabolism , 2008, Anesthesiology.

[12]  M. Haberl,et al.  Three haplotypes associated with CYP2A6 phenotypes in Caucasians , 2005, Pharmacogenetics and genomics.

[13]  M. Wortham,et al.  Expression of Constitutive Androstane Receptor, Hepatic Nuclear Factor 4α, and P450 Oxidoreductase Genes Determines Interindividual Variability in Basal Expression and Activity of a Broad Scope of Xenobiotic Metabolism Genes in the Human Liver , 2007, Drug Metabolism and Disposition.

[14]  E. Kharasch,et al.  Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone , 2004, Clinical pharmacology and therapeutics.

[15]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[16]  F. Guengerich,et al.  Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. , 2000, Archives of biochemistry and biophysics.

[17]  P. Watkins,et al.  Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. , 1987, The Journal of clinical investigation.

[18]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[19]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[20]  U. Zanger,et al.  Genetics, Epigenetics, and Regulation of Drug‐Metabolizing Cytochrome P450 Enzymes , 2014, Clinical pharmacology and therapeutics.

[21]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[22]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[23]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[24]  M. Wester,et al.  CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[25]  A. Rostami-Hodjegan,et al.  Protein expression of various hepatic uridine 5′‐diphosphate glucuronosyltransferase (UGT) enzymes and their inter‐correlations: a meta‐analysis , 2014, Biopharmaceutics & drug disposition.

[26]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[27]  Eric F. Johnson,et al.  DIAZEPAM METABOLISM BY CDNA-Expressed Human 2 C P 450 S Identification of P 4502 C 18 and P 4502 C 19 as Low KM Diazepam N-Demethylases , 1997 .

[28]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[29]  S. Yamaguchi,et al.  No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.

[30]  Katrin Marcus,et al.  Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver , 2009, Proteomics.

[31]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[32]  F. Gonzalez,et al.  Inhibitory monoclonal antibody to human cytochrome P450 2B6. , 1998, Biochemical pharmacology.

[33]  A. Daly,et al.  Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. , 2000, Biochemical pharmacology.

[34]  R. Hines,et al.  Ontogeny of human hepatic cytochromes P450 , 2007, Journal of biochemical and molecular toxicology.

[35]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[36]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[37]  R. Kato,et al.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.

[38]  P. Armitage,et al.  Statistical methods in medical research , 1971 .

[39]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  Colin White,et al.  Methods in Medical Research , 1955, The Yale Journal of Biology and Medicine.

[41]  M. Rieder,et al.  Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects , 2010, Drug Metabolism and Disposition.

[42]  Tetsuya Terasaki,et al.  Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. , 2011, Journal of pharmaceutical sciences.

[43]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[44]  S. Hall,et al.  DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL , 2005, Drug Metabolism and Disposition.

[45]  D. Murry,et al.  Significance Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical , 2014 .

[46]  M. Moya,et al.  Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. , 2009, Current drug metabolism.

[47]  J. Schwartz,et al.  Race and sex influence clearance of nifedipine: Results of a population study , 2000, Clinical pharmacology and therapeutics.

[48]  H. Yamazaki,et al.  Characterization of cytochrome P-450 2B6 in human liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[49]  C. V. van Buren,et al.  DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY , 1986, Transplantation.

[50]  O. Olesen,et al.  Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations , 2001, Journal of clinical pharmacology.

[51]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[52]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[53]  G. Tucker,et al.  In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. , 1999, Pharmacogenetics.

[54]  A. Rostami-Hodjegan,et al.  Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics , 2014, Drug Metabolism and Disposition.

[55]  Jennifer B Dennison,et al.  Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes , 2007, Journal of Pharmacology and Experimental Therapeutics.

[56]  M. Fromm,et al.  Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.

[57]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[58]  J. Lipscomb,et al.  Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. , 2000, Regulatory toxicology and pharmacology : RTP.

[59]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[60]  M. Ingelman-Sundberg,et al.  CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele , 2005, Pharmacogenetics and genomics.

[61]  J. Brockmöller,et al.  Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[62]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[63]  I. Walter‐Sack,et al.  Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[64]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[65]  B. Burchell,et al.  A Novel Method for the Immunoquantification of UDP-Glucuronosyltransferases in Human Tissue , 2011, Drug Metabolism and Disposition.

[66]  Jennifer B Dennison,et al.  A gel‐free MS‐based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes , 2008, Proteomics.

[67]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[68]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[69]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[70]  Tetsuya Terasaki,et al.  Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.

[71]  A. Rostami-Hodjegan,et al.  Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations , 2010, Biopharmaceutics & drug disposition.

[72]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[73]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[74]  A. Rettie,et al.  Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[75]  M. Wiese,et al.  Predicted metabolic drug clearance with increasing adult age. , 2013, British journal of clinical pharmacology.

[76]  D. Stresser,et al.  Monospecific antipeptide antibody to cytochrome P-450 2B6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.